4. Rajiv Agarwal, DanWilson, Amer Joseph, et al. Incidence and predictors of hyperkalemia in patientswith CKD and T2D in the FIDELIO-DKD trial. WCN21-0607. 5.梅长林, 陈晓农, 郝传明, 等. 慢性肾脏病高钾血症风险评...
December 17, 2020 1 min read Save FIDELIO-DKDAdd topic to email alerts CV outcomes of finerenone (Bayer) vs. placebo in patients with type 2 diabetes and chronic kidney disease.Read more from Trial Scorecards View all May 18, 2023 1 min read Save UK Mini Mitral May 18, 2023 1 ...
hyperkalemiamineralocorticoid receptor antagonistBackground Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type 2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia with finerenone and placebo in FIDELIO-DKD.Methods This post hoc safety ...
FIDELIO-DKD is a large trial looking at a non-steroidal mineralocorticoid receptor antagonist or MRA, that is called finerenone compared against placebo in 5734 patients with type 2 diabetes, and CKD with estimated glomerular filtration rate (EGFR) between 25 and 75. The primary endpoint of this...
Aims:This prespecified analysis of the FIDELIO-DKD trial compared the effects of finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history of heart failure (HF). Methods an...
关键词: Cardiorenal chronic kidney disease clinical trial finerenone race type 2 diabetes DOI: 10.1016/j.xkme.2023.100730 收藏 引用 批量引用 报错 分享 全部来源 求助全文 dx.doi.org NCBI 相似文献Collaborative Multidisciplinary Workshop Report: Clinical Antimicrobial Trials for Primary and Secondary ...
POS-829 Incidence and predictors of hyperkalaemia in patients with CKD and T2D in the FIDELIO-DKD trialdoi:10.1016/j.ekir.2021.03.867R. AgarwalA. JosephP. RossingB. PittG. Bakris LKidney International Reports
This study aims to assess if these criteria similarly apply to the Canadian population.We applied the FIDELIO and FIGARO trial criteria to Canadians with T2D in a community endocrinology setting, who were already optimized for renal risk with RAAS and SGLT2 therapy.Of 369 individuals with T2D ...